Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 13/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656696 | 1.00 | PIK3CB (0.49) | PIK3CBABCB1PRMT5WDR77 | |
| SCHEMBL4564652 | 1.00 | PIK3CB (0.49) | PIK3CBABCB1PRMT5WDR77 | |
| SCHEMBL4543104 | 0.94 | PIK3CB (0.48) | PIK3CBABCB1PRMT5WDR77 | |
| SCHEMBL16798230 | 0.94 | PIK3CB (0.48) | PIK3CBABCB1PRMT5WDR77 | |
| SCHEMBL4542989 | 0.94 | PIK3CB (0.48) | PIK3CBABCB1PRMT5WDR77 | |
| SCHEMBL4565204 | 0.94 | PIK3CB (0.48) | PIK3CBPRMT5WDR77 | |
| SCHEMBL4565471 | 0.94 | PIK3CB (0.48) | PIK3CBABCB1PRMT5WDR77 | |
| SCHEMBL4565205 | 0.94 | PIK3CB (0.48) | PIK3CBPRMT5WDR77 | |
| SCHEMBL4565470 | 0.94 | PIK3CB (0.48) | PIK3CBABCB1PRMT5WDR77 | |
| SCHEMBL4565313 | 0.93 | PIK3CB (0.48) | PIK3CBABCB1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303134-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | claimed |
| EP-3077003-A1 | COMBINATION OF PI3K-INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-12 | — | — | EP | claimed |
| WO-2016087488-A1 | ADMINISTRATION REGIME FOR AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | claimed |
| WO-2016087490-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | claimed |
| WO-2015082376-A2 | USE OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | claimed |
| WO-2015082378-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-11 | — | — | WO | claimed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| EP-2638044-B1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER IP GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-9730943-B2 | Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730943-B2 | Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9675616-B2 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9675616-B2 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20140113896-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113896-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2638045-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303134-A1 | COMBINATION OF PI3K-INHIBITORS | PIK3CA, PIK3R5, PIK3CD | PIK3CB 12/4885ABCB1 581/4885PRMT5 1385/4885 |
| US-20140113896-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | VEGFA, CCNA1, CCND2 | PIK3CB 1164/4885ABCB1 591/4885PRMT5 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.